全文获取类型
收费全文 | 6517篇 |
免费 | 460篇 |
国内免费 | 23篇 |
专业分类
耳鼻咽喉 | 27篇 |
儿科学 | 267篇 |
妇产科学 | 81篇 |
基础医学 | 880篇 |
口腔科学 | 164篇 |
临床医学 | 683篇 |
内科学 | 1389篇 |
皮肤病学 | 56篇 |
神经病学 | 633篇 |
特种医学 | 353篇 |
外科学 | 832篇 |
综合类 | 40篇 |
预防医学 | 453篇 |
眼科学 | 74篇 |
药学 | 676篇 |
中国医学 | 8篇 |
肿瘤学 | 384篇 |
出版年
2023年 | 29篇 |
2022年 | 30篇 |
2021年 | 84篇 |
2020年 | 75篇 |
2019年 | 112篇 |
2018年 | 122篇 |
2017年 | 139篇 |
2016年 | 127篇 |
2015年 | 102篇 |
2014年 | 137篇 |
2013年 | 296篇 |
2012年 | 323篇 |
2011年 | 287篇 |
2010年 | 207篇 |
2009年 | 186篇 |
2008年 | 328篇 |
2007年 | 339篇 |
2006年 | 287篇 |
2005年 | 316篇 |
2004年 | 294篇 |
2003年 | 307篇 |
2002年 | 255篇 |
2001年 | 212篇 |
2000年 | 185篇 |
1999年 | 198篇 |
1998年 | 90篇 |
1997年 | 66篇 |
1996年 | 78篇 |
1995年 | 66篇 |
1994年 | 57篇 |
1993年 | 67篇 |
1992年 | 141篇 |
1991年 | 138篇 |
1990年 | 126篇 |
1989年 | 158篇 |
1988年 | 124篇 |
1987年 | 125篇 |
1986年 | 115篇 |
1985年 | 75篇 |
1984年 | 78篇 |
1983年 | 58篇 |
1982年 | 40篇 |
1981年 | 40篇 |
1980年 | 30篇 |
1979年 | 56篇 |
1978年 | 35篇 |
1977年 | 31篇 |
1976年 | 27篇 |
1975年 | 26篇 |
1971年 | 33篇 |
排序方式: 共有7000条查询结果,搜索用时 15 毫秒
101.
102.
Susanna Jernelöv Erik Forsell Henrietta Westman Ylva Eriksson Dufva Nils Lindefors Viktor Kaldo Martin Kraepelien 《Journal of sleep research》2023,32(2):e13759
Cognitive behavioural therapy for insomnia is efficacious and recommended for insomnia, but availability is scarce. Cognitive behavioural therapy for insomnia self-help interventions could increase availability, especially if unguided. Optimizing cognitive behavioural therapy for insomnia methods and system user-friendliness, we developed a short, digital, self-help programme—FastAsleep—based on the behavioural components of sleep restriction and stimulus control. This study investigated its feasibility and preliminary effects. Thirty media-recruited participants with moderate to severe insomnia were assessed via telephone before using FastAsleep for 4 weeks, and were interviewed afterwards. Self-ratings with web questionnaires were conducted at screening, pre-, mid- and post-treatment, and at 3-month follow-up. Primary outcomes were feasibility (credibility, adherence, system user-friendliness and adverse effects), and secondary outcomes were changes in symptom severity (insomnia, depression and anxiety). Adherence was generally high, participants' feasibility ratings were favourable, and adverse effects matched previously reported levels for cognitive behavioural therapy for insomnia. Symptoms of insomnia decreased after the treatment period (Hedge's g = 1.79, 95% confidence interval = 1.20–2.39), as did symptoms of depression and anxiety. FastAsleep can be considered feasible and promising for alleviating insomnia symptoms among patients fit for self-care. Future controlled trials are needed to establish the efficacy of FastAsleep and its suitability in a stepped care model. 相似文献
103.
J. W. Eriksson J. Fowelin V. Urbanavicius 《European journal of clinical pharmacology》1994,46(5):469-472
We have evaluated the short-term effects of amiloride on insulin action in vivo, since amiloride is known to impair insulin action in vitro.Seven healthy subjects were treated according to a randomized, double-blind, cross-over protocol. The treatment periods were 3 days each with amiloride 15 mg daily and placebo. Insulin action on glucose turnover was assessed directly after each treatment period with the hyper-insulinaemic euglycaemic glucose clamp technique.At the two insulin concentrations studied ( 30 mU·l–1 and 200 mU·l–1), the glucose infusion rate required to maintain constant euglycaemia did not differ after either amiloride or placebo. The rates of glucose production and utilization were also similar, whereas the so-called insulin sensitivity index at the lower insulin concentration was significantly reduced (by about 15 %) after amiloride. Moreover, amiloride produced significantly higher fasting insulin and C-peptide concentrations, whereas fasting glucose and NEFA concentrations were unaltered.In conclusion, these data suggest that short-term amiloride slightly impairs insulin sensitivity with respect to glucose uptake. However, overall glucose homoeostasis does not appear to be affected, probably due to a compensatory rise in plasma insulin. 相似文献
104.
105.
Viera Reichelová Gunnar Juliusson Tatiana Spasokoukotskaja Staffan Eriksson Jan Liliemark 《Cancer chemotherapy and pharmacology》1995,36(6):524-529
2-Chloro-2-deoxyadenosine (CdA, Cladribine), is a purine antimetabolite currently under investigation in phase II clinical trials for the treatment of lymphoid malignancies. Significant differences in CdA toxicity between mice and humans were observed during phase I clinical evaluation. For the elucidation of interspecies differences in drug toxicity the pharmacokinetics of CdA after subcutaneous injection and the kinetic properties of the CdA-phosphorylating enzyme, deoxycytidine kinase (dCK), were compared in mice and humans. The ratio of the dose lethal to 10% of mice (LD10) to the maximum tolerated dose (MTD) in humans was 50 and the ratio of the area under the curve obtained at approximately one-half the LD10 (AUCapprox. one-half the LD
10)/AUCMTD was 49. A significant interspecies difference was observed in the kinetic properties of dCK, the main CdA-activating enzyme. With CdA as a substrate, the Michaelis constant (K
m) of dCK in crude extracts of mouse thymus was 10 times higher than that in human thymus. An approximately 9-fold interspecies difference in maximum velocity (Vmax)/K
m indicated a higher efficiency of dCK for CdA in humans than in mice. The peak plasma concentration was 210 times higher and exceeded theK
m in mice. Initial and terminal half-lives were approximately 7 times shorter in mice and trough levels were similar in mice and humans. Thus, the differences in AUCs at equitoxic doses are largely explained by differences in the target enzyme properties and the pharmacokinetic pattern. The observed lower tolerance for CdA in humans as compared with mice confirms the view that antimetabolites may not be good candidates for pharmacokinetically guided dose-escalation schemes unless detailed information on interspecies variability in drug bioactivation is available. 相似文献
106.
A. Tommy Bergenheim Björn Zackrisson Jörgen Elfverson Göran Roos Roger Henriksson 《Journal of neuro-oncology》1995,23(3):191-200
Summary Estramustine-phosphate (EMP), a combination of nornitrogen mustard and 17-estradiol, has been demonstrated to exert specific antiproliferative effects on human glioma cellsin vitro. The cytotoxic effect is, at least partially, mediated by inhibiting microtubule function. In this study the combined effect of EMP and radiation was evaluated in the human glioma cell-lines, 251-MG and 105-MG,in vitro, and in the rat glioma BT4Cin vitro andin vivo. In all cell-lines an additive effect of EMP and radiation was obtainedin vitro. Assuming equal effect of EMP is obtained in subsequent radiation fractions, the cell kill will be increased from 2–3 to 5–10 logs if delivering 30 fractions of 2 Gy combined with EMP. In the BT4C rat model the combined effect was found to be synergistic. Flow cytometry demonstrated an arrest in G2/M phase in all cell-lines after EMP treatment. This block in G2/M phase in addition to the previously demonstrated induction of free oxygen radicals, and the increase of blood flow with an assumed subsequent increase of oxygenation, might provide an explanation for the observed radiosensitizing effect of estramustine. 相似文献
107.
Previous experimental studies suggest that diabetic embryopathy is associated with an excess of radical oxygen species (ROS), as well as with a disturbance of prostaglandin (PG) metabolism. We aimed to investigate the relationship between these pathways and used hyperglycemia in vitro (embryo culture for 24-48 h) and maternal diabetes in vivo to affect embryonic development. Subsequently, we assessed lipid peroxidation and gene expression of cyclooxygenase (COX)-1 and -2 and measured the concentration of prostaglandin E2 (PGE2) in embryos and membranes. Both hyperglycemia in vitro and maternal diabetes in vivo caused embryonic dysmorphogenesis and increased embryonic levels of 8-epi-PGF2alpha, an indicator of lipid peroxidation. Addition of N-acetylcysteine (NAC) to the culture medium normalized the morphology and 8-epi-PGF2alpha concentration of the embryos exposed to high glucose. Neither hyperglycemia nor diabetes altered COX-1 expression, but embryonic COX-2 expression was diminished on gestational day 10. The PGE2 concentration of day 10 embryos and membranes was decreased after exposure to high glucose in vitro or diabetes in vivo. In vitro addition of NAC to high glucose cultures largely rectified morphology and restored PGE2 concentration, but without normalizing the COX-2 expression in embryos and membranes. Hyperglycemia/diabetes-induced downregulation of embryonic COX-2 gene expression may be a primary event in diabetic embryopathy, leading to lowered PGE2 levels and dysmorphogenesis. Antioxidant treatment does not prevent the decrease in COX-2 mRNA levels but restores PGE2 concentrations, suggesting that diabetes-induced oxidative stress aggravates the loss of COX-2 activity. This may explain in part the antiteratogenic effect of antioxidant treatment. 相似文献
108.
To investigate possible changes in somatostatin receptor expression during treatment with high dose lanreotide, eight patients with neuroendocrine tumors were investigated by [111In-DTPA-D-Phe1]-octreotide scintigraphy before and during treatment. The spleen-to-background ratio decreased in all patients, whereas tumor-to-background ratio revealed a heterogeneous pattern with an average increase of 50% (−79% to +1,087%). This finding indicates that lanreotide treatment may influence the binding of radioactively labeled somatostatin to the spleen, while changes in the binding to functioning somatostatin receptors in tumor cells are more complex and not clearly related to treatment. 相似文献
109.
Eriksson S 《Obesity surgery》1999,9(5):499-501
Background: Breast reduction surgery is common in females; however, in males it is mainly due to gynecomastia. After weight
reduction following obesity surgery, it is a problem in women, but also in some men. Method: One patient is described in whom
the weight reduction declined from BMI 52 to BMI 36 after vertical banded gastroplasty, giving the patient ptotic breasts.
Results: The patient underwent reduction mammaplasty with lateral single-based cutaneous flaps, and a total of 1,000 g was
removed. Conclusion: Reduction mammoplasty can be performed in males with the methods used today, after successful weight
loss following obesity surgery. 相似文献
110.